Diffuse large B-cell lymphoma trials in Argentina
3 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Where
- Buenos Aires, Caba., CABA, Mar del Plata, Pilar, Rosario, San Juan, San Miguel de Tucumán
- Age
- 18 years and over
- People
- 1,046 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06717347 · EU 2024-515566-13-00 - Phase 2/3Taking peopleA Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
- Where
- Buenos Aites, CABA, Ciudad Autonoma de Buenos Aires, Córdoba, Mar del Plata
- Age
- 18 years and over
- People
- 290 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT05139017 · EU 2022-502646-27-00 - No phaseTaking peopleReal-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma
- Where
- Buenos Aires, Ciudad Autonoma de Buenos Aire, Córdoba, Pilar
- Age
- 18 years and over
- People
- 700 worldwide
- Run by
- AbbVie
See details and how to joinNCT06830759